Form 4: Nuvalent CEO Sells Shares Under 10b5-1 Plan

Nuvalent, Inc. President and CEO James Richard Porter sold 30,000 shares of Class A Common Stock for $18.93 per share, as part of a pre-arranged trading plan.

Summary

• James Richard Porter, President and CEO of Nuvalent, Inc., executed a transaction on July 6, 2026.
• He acquired 30,000 shares of Class A Common Stock at a price of $18.93 per share.
• Concurrently, he disposed of 30,000 shares of Class A Common Stock at a weighted average price of $123.72 per share, with individual sales ranging from $123.66 to $123.78.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 4, 2025.
• Following these transactions, Porter beneficially owns 324,879 shares of Class A Common Stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the significant sale by the CEO, despite it being executed under a pre-planned Rule 10b5-1 trading plan.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-sensitive trading activity.
• The CEO's continued direct ownership of 324,879 shares suggests ongoing significant investment in the company.

Negatives

• A significant number of shares (30,000) were sold by the CEO, which could be perceived negatively by the market.
• The sale price ($123.72 average) is substantially higher than the acquisition price ($18.93), indicating a substantial profit for the CEO on this portion of his holdings.

Risks

• Potential for negative market perception due to the CEO's sale of a considerable number of shares, even if executed under a pre-planned trading strategy.
• The significant difference between the acquisition and sale price might raise questions about the timing and motivation behind the Rule 10b5-1 plan.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.66 to $123.78, inclusive.
• The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.
• The shares underlying this option are fully vested.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event for executives. The key is to analyze the volume of shares sold relative to the executive's total holdings and the company's overall performance and outlook. For Nuvalent, a biopharmaceutical company, such transactions are often scrutinized in the context of clinical trial progress and regulatory approvals.

Stakeholder Impact

• Shareholders may view the CEO's sale of a significant number of shares with concern, potentially impacting short-term stock price sentiment.
• Employees may also be influenced by the CEO's stock sale, though the Rule 10b5-1 plan mitigates concerns about insider trading based on non-public information.

Next Steps

• The reporting person undertakes to provide further details on share sales upon request.
• Continued monitoring of insider transactions and company performance is advised.

Key Dates

Recommendation

The filing reports a routine insider sale under a pre-established trading plan. While the sale itself can create short-term negative sentiment, the execution via a 10b5-1 plan and the continued substantial beneficial ownership by the CEO suggest this is a portfolio management action rather than a reflection of negative company outlook. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Nuvalent's business prospects.

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, CEO, Class A Common Stock, Beneficial Ownership, Securities Exchange Act